Mitral Valve Disease Therapeutics Market By Drug class, By Age group, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "Mitral Valve Disease Therapeutics Market," The mitral valve disease therapeutics market was valued at $607.74 million in 2022, and is estimated to reach $803.4 million by 2032, growing at a CAGR of 2.8% from 2023 to 2032.

Mitral Valve Disease Therapeutics Market - IMG1

The major factor driving the growth of the mitral valve disease therapeutics market is increase in prevalence of mitral valve conditions. There has been an increase in the number of patients diagnosed with mitral valve diseases such as mitral regurgitation, mitral prolapse, and mitral stenosis. For instance, Journal of Clinical Medicine 2022, stated that, mitral regurgitation is the second most common valvular heart disease in Europe and the most common in the U.S., with a prevalence of 9.3% in the population aged over 75 years. Thus, rise in prevalence of mitral valve conditions results in demand for therapeutics and propels the market growth.

Further, mitral valve disease can be caused by various factors, such as rheumatic fever and congenital heart defects. Rheumatic fever is an inflammatory disease that can occur after a streptococcal infection, leading to inflammation that can spread to the heart, causing damage to the heart valves, including the mitral valve. Thus, this damage can lead to mitral valve disease, which can cause symptoms such as shortness of breath, fatigue, chest pain, and heart palpitations. In addition, congenital heart defects are structural abnormalities that are present at birth. Some congenital heart defects can affect the function of the mitral valve, leading to mitral valve disease. Thus, to manage the symptoms of mitral valve disease, therapeutics such as beta blockers, diuretics, and calcium channel blockers are prescribed, thereby driving the growth of the market.

Furthermore, rise in mitral valve replacement procedures and adoption of therapeutics is expected to propel the market growth. For instance, anticoagulants are commonly used to manage mitral valve disease and prevent blood clots, which can lead to serious complications such as stroke. Thus, rise in adoption of anticoagulants drives the market growth.

Further, rise in the incidence of mitral valve diseases can be attributed to several factors, such as aging population and increase in risk factors such as high blood pressure, diabetes, and obesity. As the population ages, the risk of developing mitral valve disease increases. This is because the valve can become damaged or weakened over time, making it more prone to malfunction. In addition, the rise in risk factors such as high blood pressure and obesity can increase the risk of developing mitral valve disease. Moreover, rise in awareness of mitral valve diseases among patients and healthcare professionals has led to earlier diagnosis and treatment, driving demand for medical interventions. Governments around the world are investing in research and development of new treatments for mitral valve disease, which has led to the development of novel therapeutics.

In addition, increased awareness about the symptoms and risk factors associated with mitral valve disease has led to more people seeking medical treatment for the condition, which has further driven the growth of the market. However, availability of other treatment options for mitral valve disease is expected to restrain the growth of mitral valve disease therapeutics market. There are several alternative treatment options available for mitral valve disease, such as surgical interventions and transcatheter procedures. These alternative options may be preferred by some patients or may be recommended by healthcare providers based on individual patient needs, thus restraining the growth of market.

The global mitral valve disease therapeutics market is segmented into drug class, age group, distribution channel, and region. On the basis of drug class, the market is categorized into beta blockers, diuretics, anticoagulants, and others. As per age group, the market is categorized into below 55 years and above 55 years. According to distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global mitral valve disease therapeutics market are Zydus Lifesciences Limited, Pfizer Inc., Bayer AG, Novartis AG, Viatris Inc., Alembic Ltd., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Limited, and Sanofi.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mitral valve disease therapeutics market analysis from 2022 to 2032 to identify the prevailing mitral valve disease therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the mitral valve disease therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global mitral valve disease therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution channel

Hospital pharmacies
Drug store and retail pharmacies
Online providers

By Drug class

Beta blockers
Diuretics
Anticoagulants
Others

By Age group

Below 55 years
Above 55 years

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Bayer AG
Novartis AG
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Viatris Inc.
Sun Pharmaceutical Industries Limited
Cipla Ltd
Zydus Lifesciences Limited
Sanofi
Alembic Ltd

Product Code: A74639

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increasing prevalence of mitral valve diseases
  - 3.4.1.2. Rise in adoption of pharmaceutical drugs to manage mitral valve disease symptoms
  - 3.4.1.3. Rise in geriatric population

3.4.2. Restraints
- 3.4.2.1. Availability of alternative treatment options

3.4.3. Opportunities
- 3.4.3.1. Growth opportunities in emerging markets

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Beta blockers
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Diuretics
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Anticoagulants
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Others
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country

CHAPTER 5: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Below 55 years
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Above 55 years
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug store and retail pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Drug class
- 7.2.3. Market size and forecast, by Age group
- 7.2.4. Market size and forecast, by Distribution channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Drug class
  - 7.2.5.1.3. Market size and forecast, by Age group
  - 7.2.5.1.4. Market size and forecast, by Distribution channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Drug class
  - 7.2.5.2.3. Market size and forecast, by Age group
  - 7.2.5.2.4. Market size and forecast, by Distribution channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Drug class
  - 7.2.5.3.3. Market size and forecast, by Age group
  - 7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Drug class
- 7.3.3. Market size and forecast, by Age group
- 7.3.4. Market size and forecast, by Distribution channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Drug class
  - 7.3.5.1.3. Market size and forecast, by Age group
  - 7.3.5.1.4. Market size and forecast, by Distribution channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Drug class
  - 7.3.5.2.3. Market size and forecast, by Age group
  - 7.3.5.2.4. Market size and forecast, by Distribution channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Drug class
  - 7.3.5.3.3. Market size and forecast, by Age group
  - 7.3.5.3.4. Market size and forecast, by Distribution channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Drug class
  - 7.3.5.4.3. Market size and forecast, by Age group
  - 7.3.5.4.4. Market size and forecast, by Distribution channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Drug class
  - 7.3.5.5.3. Market size and forecast, by Age group
  - 7.3.5.5.4. Market size and forecast, by Distribution channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Drug class
  - 7.3.5.6.3. Market size and forecast, by Age group
  - 7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Drug class
- 7.4.3. Market size and forecast, by Age group
- 7.4.4. Market size and forecast, by Distribution channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Drug class
  - 7.4.5.1.3. Market size and forecast, by Age group
  - 7.4.5.1.4. Market size and forecast, by Distribution channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Drug class
  - 7.4.5.2.3. Market size and forecast, by Age group
  - 7.4.5.2.4. Market size and forecast, by Distribution channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Drug class
  - 7.4.5.3.3. Market size and forecast, by Age group
  - 7.4.5.3.4. Market size and forecast, by Distribution channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Drug class
  - 7.4.5.4.3. Market size and forecast, by Age group
  - 7.4.5.4.4. Market size and forecast, by Distribution channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Drug class
  - 7.4.5.5.3. Market size and forecast, by Age group
  - 7.4.5.5.4. Market size and forecast, by Distribution channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Drug class
  - 7.4.5.6.3. Market size and forecast, by Age group
  - 7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Drug class
- 7.5.3. Market size and forecast, by Age group
- 7.5.4. Market size and forecast, by Distribution channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Drug class
  - 7.5.5.1.3. Market size and forecast, by Age group
  - 7.5.5.1.4. Market size and forecast, by Distribution channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Drug class
  - 7.5.5.2.3. Market size and forecast, by Age group
  - 7.5.5.2.4. Market size and forecast, by Distribution channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Drug class
  - 7.5.5.3.3. Market size and forecast, by Age group
  - 7.5.5.3.4. Market size and forecast, by Distribution channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Drug class
  - 7.5.5.4.3. Market size and forecast, by Age group
  - 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Zydus Lifesciences Limited
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. Pfizer Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Bayer AG
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Novartis AG
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. Viatris Inc.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. Alembic Ltd
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Sun Pharmaceutical Industries Limited
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Cipla Ltd
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Teva Pharmaceutical Industries Ltd.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Sanofi
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance